LRIG3 was, in contrast to LRIG1 and LRIG2, significantly increased in glioma compared to control tissue (1.354 ± 0.89 vs. 0.746 ± 0.242, p = 0.039, Figures 7A and 8A), with highest difference to grade II glioma (1.556 ± 0.702 vs. 0.746 ± 0.242, p = 0.0.0002, Figure 7B). This evidence concerns the gene LRIG1 and central nervous system cancer.